JP6117333B2 - 免疫関連疾患及び酸化的ストレス関連疾患の予防または治療用組成物 - Google Patents
免疫関連疾患及び酸化的ストレス関連疾患の予防または治療用組成物 Download PDFInfo
- Publication number
- JP6117333B2 JP6117333B2 JP2015503120A JP2015503120A JP6117333B2 JP 6117333 B2 JP6117333 B2 JP 6117333B2 JP 2015503120 A JP2015503120 A JP 2015503120A JP 2015503120 A JP2015503120 A JP 2015503120A JP 6117333 B2 JP6117333 B2 JP 6117333B2
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- composition
- arsenic
- white
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 44
- 201000010099 disease Diseases 0.000 title claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 38
- 230000036542 oxidative stress Effects 0.000 title claims description 16
- 150000001495 arsenic compounds Chemical class 0.000 claims description 35
- 210000004185 liver Anatomy 0.000 claims description 27
- 239000004576 sand Substances 0.000 claims description 16
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 235000008632 Santalum album Nutrition 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 229940093920 gynecological arsenic compound Drugs 0.000 claims description 12
- 240000007594 Oryza sativa Species 0.000 claims description 11
- 235000007164 Oryza sativa Nutrition 0.000 claims description 11
- 229910052785 arsenic Inorganic materials 0.000 claims description 11
- 235000015278 beef Nutrition 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- -1 clove Chemical class 0.000 claims description 11
- 235000009566 rice Nutrition 0.000 claims description 11
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 10
- 230000001988 toxicity Effects 0.000 claims description 10
- 231100000419 toxicity Toxicity 0.000 claims description 10
- 244000061456 Solanum tuberosum Species 0.000 claims description 9
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 9
- 210000004556 brain Anatomy 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 244000066764 Ailanthus triphysa Species 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 claims description 5
- 244000061458 Solanum melongena Species 0.000 claims description 5
- 235000002597 Solanum melongena Nutrition 0.000 claims description 5
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 230000006793 arrhythmia Effects 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- JMBNQWNFNACVCB-UHFFFAOYSA-N arsenic tribromide Chemical compound Br[As](Br)Br JMBNQWNFNACVCB-UHFFFAOYSA-N 0.000 claims description 3
- 229940077468 arsenic tribromide Drugs 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 206010016946 Food allergy Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- OEYOHULQRFXULB-UHFFFAOYSA-N arsenic trichloride Chemical compound Cl[As](Cl)Cl OEYOHULQRFXULB-UHFFFAOYSA-N 0.000 claims description 2
- IKIBSPLDJGAHPX-UHFFFAOYSA-N arsenic triiodide Chemical compound I[As](I)I IKIBSPLDJGAHPX-UHFFFAOYSA-N 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 244000061408 Eugenia caryophyllata Species 0.000 claims 9
- 241000221035 Santalaceae Species 0.000 claims 9
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229960001728 melarsoprol Drugs 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 82
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 43
- 230000000694 effects Effects 0.000 description 39
- 239000006187 pill Substances 0.000 description 39
- 230000037396 body weight Effects 0.000 description 34
- 239000002158 endotoxin Substances 0.000 description 28
- 229920006008 lipopolysaccharide Polymers 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 22
- 210000002540 macrophage Anatomy 0.000 description 21
- 230000028327 secretion Effects 0.000 description 21
- 241000700159 Rattus Species 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 210000005228 liver tissue Anatomy 0.000 description 16
- 231100000135 cytotoxicity Toxicity 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 14
- 210000003494 hepatocyte Anatomy 0.000 description 13
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000011076 safety test Methods 0.000 description 12
- 229960001340 histamine Drugs 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 10
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 229940118019 malondialdehyde Drugs 0.000 description 10
- 241000283690 Bos taurus Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 6
- 244000223014 Syzygium aromaticum Species 0.000 description 6
- 229920002055 compound 48/80 Polymers 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000004006 olive oil Substances 0.000 description 6
- 235000008390 olive oil Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 240000000513 Santalum album Species 0.000 description 5
- 239000007979 citrate buffer Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000003240 portal vein Anatomy 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000008458 response to injury Effects 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000227129 Aconitum Species 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 244000003363 Allium ursinum Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000751139 Beauveria bassiana Species 0.000 description 1
- 241001002658 Bellamya aeruginosa Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 229910002566 KAl(SO4)2·12H2O Inorganic materials 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000316658 Sauromatum giganteum Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- BMSYAGRCQOYYMZ-UHFFFAOYSA-N [As].[As] Chemical compound [As].[As] BMSYAGRCQOYYMZ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 235000011126 aluminium potassium sulphate Nutrition 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000009058 cervical adenitis Diseases 0.000 description 1
- 208000012751 cervical lymphadenitis Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910052956 cinnabar Inorganic materials 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000000138 effect on histamine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000001752 female genitalia Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical class O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- QXKXDIKCIPXUPL-UHFFFAOYSA-N sulfanylidenemercury Chemical compound [Hg]=S QXKXDIKCIPXUPL-UHFFFAOYSA-N 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
Description
本発明は丁香、全蠍、鏡面朱砂、牛黄、ビャッキョウサン、白附子、枯白礬、紫河車、竜脳及び砒素化合物を含む、砒素化合物の毒性が効果的に減少された免疫関連疾患または酸化的ストレス関連疾患の予防または治療用組成物に関するものである。
本発明による砒素化合物含有丸薬を製造するために、それぞれの薬剤(砒素化合物として砒霜(三酸化砒素)、丁香、全蠍、鏡面朱砂、牛黄、ビャッキョウサン、白附子、枯白礬、紫河車、竜脳)を京東市場で選別して購入した。その後、砒霜40g、丁香200g、全蠍2400g、鏡面朱砂250g、牛黄300g、ビャッキョウサン600g、白附子450g、枯白礬 600g、紫河車2400g及び竜脳30gをそれぞれ秤量して粉砕した後、混合機(G&S Korea)で混合する。その後、混合した薬剤の結合のために、適量の蜂蜜を投入して攪拌し、製造された練り物を製丸機(大成製薬機械製作所で注文制作、PM TECK自動化機器)で抜いた後、切断機(大成製薬機械製作所で注文制作、PM TECK自動化機器)に投入して丸薬を製造した。上記のように製造された丸薬を以下の試験で用いた。
四塩化炭素(CCl4)は代表的な肝毒性化学物質で肝細胞の損傷に係わる研究に広く利用されている。四塩化炭素は肝細胞内での酵素性代謝過程で生成されるフリーラジカルが蓄積して、細胞膜の脂質過酸化(lipid peroxidation)、タンパク質の酸化的変形またはDNA損傷をもたらす酸化的ストレス(oxidative stress)で細胞損傷を誘発する。
8週齢の雄Spargue−Dawley Rat(samtako、韓国)を購入して、世明大学清浄動物飼育室で、温度23±1℃、湿度50±5%で、明るいところで12時間、暗いところで12時間の条件で5日間適応させながら、体重が平均235gに達したとき実験に利用した。全実験期間中、飼料(第一製糖 韓国)と飲水は自由に摂取するようにした。本動物実験は世明大学動物実験倫理委員会の承認(smeac11−08−01)を得て実施された。
正常群(normal群)は実験開始日から毎日蒸溜水1mlを7日間経口投与し、最終投与1時間の後にオリーブオイル(1ml/体重kg)を腹腔内投与した。
検査項目
1)体重及び体重増加率
すべての動物の体重を実験開始日(1日)から4日、7日及び実験終了日(8日)に測定した。体重増加率は(7日間増加された体重/実験開始日の体重)×100で計算した。
実験終了日に剖検して肝臓を摘出し、周辺結合織を注意深く除去した後、肝臓重量を測定した。肝臓/体重比(肝臓重量/体重)×100で計算した。
オリーブオイルまたはCCl4を腹腔内投与した後24時間目にラットをエーテルで軽く麻酔し、心臓を通じて血液を採取して血清分離管に注入した。血清分離管を冷蔵状態で3,500rpmの速度で10分間遠心して血清を分離し、自動生化学分析器(Hitachimodular、Japan)を利用してmodified IFCC方法で血清ALT及びASTを測定した。測定の時、AST(Roche、USA)及びALT(Roche、USA)試薬を利用した。
肝臓の重量を測定した後、中葉(median lobe)の右側部位の一部を摘出して肝組織内脂質過酸化含量測定に用いた。
脂質過酸化含量測定はOhkawaの方法(Ohkawa et al.,J.Med.Chem.,40,pp.559−573、1997)に準じてチオバルビツール酸法(Thiobarbituric acid assay)を利用して脂質過酸化の最終産物であるマロンジアルデヒドを指標で定量した。即ち、肝組織を10倍(v/w)用量の1.15%塩化カリウム溶液に均質化して均質液を製造した。続いて、上記均質液0.2ml、8.1%ドデシル硫酸ナトリウム(SDS)0.2ml、20%酢酸(pH3.5)1.5ml、5%ブチル化ヒドロキシトルエン(Butylated hydroxytoluene)0.5ml及び0.8%チオバルビツール酸1.5mlを混合し、100℃が保持される恒温槽で60分間反応させて、室温で1時間放置した後3,000rpmで10分間遠心分離し、上層液を取って532nmでのUV分光器で吸光度を測定した。
摘出された中葉の左側部位を10%中性緩衝ホルマリン(Neutral Buffered Formalin:NBF)溶液に1日間固定し、一般のアルコール脱水過程とキシレン透明化過程を経た後パラフィンブロックを作った。5μm厚さのパラフィン薄切片を製作して、ヘマトキシリン及びエオシン染色して光学顕微鏡で病理学的所見を比較して観察した。
A.肝保護効果
1)体重の差
正常群での体重は実験期間の間増加しつづあり、実験8日には絶食によって体重が減少した。
ラットのCCl4-誘導された肝毒性での体重に対する試料物質前処理が及ぼす影響
2)肝臓重量及び肝臓/体重比の差
実験終了日に測定した肝臓重量及び肝臓/体重比は対照群が正常群に比べて全部有意に高く現われた。
ラットのCCl4で誘導された肝毒性での肝臓重量及び肝臓/体重比に対する試料物質前処理が及ぼす影響
対照群の血中ALT及びAST活性は正常群に比べて全部有意に高かった。
ラットのCCl4-誘導された肝毒性での血中ALT及びAST活性に対する試料物質前処理が及ぼす影響
対照群の肝組織中で、脂質過酸化物であるマロンジアルデヒド(MDA)の含量は正常群に比べて有意に高かった。
ラットのCCl4で誘導された肝毒性での肝組織の脂質過酸化物含量に対する試料物質前処理が及ぼす影響
正常群の肝組織は、図1のa及びbから確認することができるように、中心静脈、門脈三管、肝細胞板及び洞様毛細血管のすべての構造がよく維持されており、肝細胞も正常な構造を取っていた。対照群の肝組織では中心静脈の周りに広範囲な肝細胞壊死が観察され、壊死周辺の肝細胞は多様な大きさの恐怖変性及び脂肪変化が観察された。壊死した部位では多量の炎症細胞の浸潤が確認された。門脈三管の周りの肝細胞は比較的正常な構造を保持していた(図2のa及びb参照)。
B.安全性分析
1)体重の差
実施例1の丸薬の安全性を評価するための安全性試験群での体重及び体重増加率は正常群に比べてやや高く現われたが、有意な差はなかった(表6)。
ラットの体重に対する高濃度試料処理時(安全性試験群)の効果
実施例1の丸薬の安全性を評価するための安全性試験群での肝臓重量及び肝臓/体重比は正常群と類似に現われた(表7)。
ラット肝臓重量及び肝臓/体重比に対する高濃度試料処理時(安全性試験群)の効果
実施例1の丸薬の安全性を評価するための安全性試験群での血中ALT及びASTは全部正常群と類似するように現れた(表8)。
ラットの血中ALT及びAST活性に対する高濃度試料処理時(安全性試験群)の効果
実施例1の丸薬の安全性を評価するための安全性試験群での肝組織の中でマロンジアルデヒド(MDA)の含量は正常群に比べて有意に低かった(表9)。
ラットの肝組織内のMDA含量に対する高濃度試料処理時(安全性試験群)の効果
確認の結果、正常群の肝組織は、中心静脈、門脈三管、肝細胞板及び洞様毛細血管のすべての構造がよく保持されており、肝細胞も正常な構造を取っていた(図6のa及びb参照)。高濃度の丸薬のみを投与した安全性試験群でも肝組織は全部正常な構造を保持していた(図7のa及びb参照)。
フリーラジカル消去活性試験は化学的に安定したフリーラジカルである2,2−ジフェニル−1−ピクリルヒドラジル(DPPH)を利用して抗酸化効果を分かることができる方法として、上記DPPHは515nm〜520nmの付近で最大吸光度を有し、抗酸化活性のある物質と遇うと電子を供与しラジカル(DPPH)が消滅されて色が変わる。化学的に安定性のあるDPPHは各種抗酸化成分が内在された抽出物、飲料とオイル、純粋フェノール化合物などの抗酸化効果を分析することができる。
1)実験材料の準備
実施例1で製造された丸薬200gを精密に取った後蒸溜水2Lを添加して熱水抽出した。その後、減圧濃縮器を用いて濃縮した後、凍結乾燥して収率46.08%のきれいな粉末を製造した。この粉末を以後の実験で試料として用いた。
2−1)DPPHフリーラジカル消法能
凍結乾燥した試料を0.8、4、20、100及び200mg/mlの濃度になるように試液を調剤した後、96ウェルプレートに10μlずつ添加した。各ウェルに40μlのEtOHを添加した後、DPPH2.5mMを添加して30分間反応させた。この反応液を515nmで吸光度を測定してフリーラジカル消法能(%)を計算した。
凍結して乾燥された試料を0.8、4、20、100及び200mg/mlの濃度になるように試液を調剤した後、各試液を1mlずつ15mlのチューブに分注した。各チューブに1mM硝酸ナトリウム溶液を2mlずつ添加した後、pH1.2の塩酸溶液、pH3.0のクエン酸緩衝液及びpH6.0のクエン酸緩衝液を各チューブに7mlずつ添加し、37℃で1時間反応させた。この反応液を1mlの2%酢酸溶液及びグリス(griess)試薬を添加し、さらに15分間反応させた後、520nmで吸光度を測定して亜硝酸消法能(%)を計算した。
マウスの大食細胞であるRAW264.7細胞に試料を処理して免疫細胞に対する試料の細胞毒性を確認した。
大食細胞であるRAW264.7細胞を96ウェルプレートに各ウェル当たり0.5×104個ずつプレートに分注して24時間培養した。その後、各ウェルにLPS1μg/ml及び蛍光ビッドが付着されたIgGを処理し、試料を濃度別(10、50、100及び200μg/ml)で処理した。24時間後、各ウェルの培地を取り除いた後、40μg/mlのトリパンブルー溶液で洗浄した。洗浄されたプレートを励起(excitation)485nm及び放出(emission)535nmの蛍光波長で測定し、正常群に対する大食能の比率(%)で換算してグラフで表した。
マウス大食細胞であるRAW264.7細胞を各ウェル当たり1×104個ずつ96ウェルプレートに分注して24時間培養した。その後、各ウェルに1μg/mlのLPSを処理し、試料を濃度別(0、10、50、100及び200μg/ml)で処理した。4時間後各ウェルの培地を100μlずつ取ってグリス試薬を添加し、さらに15分間反応させた後、540nmで吸光度を測定して亜硝酸除去能(%)を計算した。
ヒスタミン分泌に対する試料の影響を確認するために、ヒト肥満細胞であるHMC細胞を利用してヒスタミン分泌量を測定した。
ヒト気管支上皮細胞であるA549細胞を利用して気管支上皮細胞に対する試料の細胞毒性を確認した。
ヒト気管支上皮細胞であるA549細胞を24ウェルプレートに1×105個ずつ分注して24時間培養した。その後、試料を各濃度別(50及び20μg/ml)で処理し、LPSを利用して炎症反応を誘導した。
実験結果は平均±SEMで表し、一方向分散分析(one−way ANOVA)を利用して統計処理した後、信頼区間(P value)が0.05より小さい場合、有意性があることと判定した。
1)DPPHフリーラジカル消法能
それぞれの試料を濃度別に試液を調剤した後、DPPHを添加してフリーラジカル消法能を測定した結果、図8で確認することができるように、0.8、4、20、100及び200mg/mlの濃度でそれぞれ6.7±2.0、17.9±1.6、49.9±8.7、76.1±6.9及び92.3±11.0%のフリーラジカル消法能を示した。試料の投与濃度が増加するほどDPPHフリーラジカル消去能が増加することを確認することができた。
試料の亜硝酸塩(nitrite)の生成抑制に対する効果を確認するために、0.8、4、20、100及び200mg/mlの試料をpH1.2の塩酸溶液、pH3.0のクエン酸緩衝液及びpH6.0のクエン酸緩衝液での亜硝酸塩の消去能力を測定した。
マウス大食細胞であるRAW264.7細胞に試料を処理して、免疫細胞に対する試料の細胞毒性を確認した。
マウス大食細胞であるRAW264.7細胞に蛍光ビッドが付着されたIgGを処理し、試料を濃度別に処理して試料の大食細胞活性に対する影響を測定した。
マウス大食細胞であるRAW264.7細胞をLPSを処理し、試料を濃度別に処理してNO生成に対する試料の影響を確認した。
ヒスタミン分泌に対する試料の影響を確認するために、ヒト肥満細胞であるHMC細胞を利用してヒスタミン分泌量を測定した。
ヒト気管支上皮細胞であるA549細胞に試料を処理して気管支上皮細胞に対する試料の細胞毒性を確認した。
試料のサイトカイン分泌に対する影響を調べるために、LPSを利用して刺激したA549細胞に試料を50及び200μg/mlを投与した。その後、RayBioヒトサイトカイン抗体アレイキットを利用してサイトカイン分泌量を測定した。
Claims (9)
- 丁香、全蠍、鏡面朱砂、牛黄、ビャッキョウサン、白附子、枯白礬、紫河車、竜脳及び砒素化合物を含む免疫関連疾患予防または治療用組成物であって、
前記組成物が砒素化合物1〜7重量部、丁香15〜25重量部、全蠍200〜270重量部、鏡面朱砂20〜30重量部、牛黄25〜35重量部、ビャッキョウサン50〜65重量部、白附子38〜48重量部、枯白礬50〜65重量部、紫河車200〜270重量部及び竜脳0.5〜6重量部を含むことを特徴とする組成物。 - 前記免疫関連疾患は、免疫介在性炎症疾患、非免疫介在性炎症疾患、感染症、免疫不全疾患及び新生物(neoplasia)からなる群で選択されることを特徴とする請求項1に記載の組成物。
- 前記免疫関連疾患は、後天性免疫欠乏症(AIDS)、肝炎、肝硬化、癌、喘息、アレルギー性鼻炎、アトピー性皮膚炎、食物過敏症またはじんま疹であることを特徴とする請求項2に記載の組成物。
- 丁香、全蠍、鏡面朱砂、牛黄、ビャッキョウサン、白附子、枯白礬、紫河車、竜脳及び砒素化合物を含む酸化的ストレス関連疾患予防または治療用組成物であって、
前記組成物が砒素化合物1〜7重量部、丁香15〜25重量部、全蠍200〜270重量部、鏡面朱砂20〜30重量部、牛黄25〜35重量部、ビャッキョウサン50〜65重量部、白附子38〜48重量部、枯白礬50〜65重量部、紫河車200〜270重量部及び竜脳0.5〜6重量部を含むことを特徴とする組成物。 - 前記酸化的ストレス関連疾患は、脂質代謝疾患、動脈硬化症、心不全症、高血圧性心臓疾患、不整脈、心筋梗塞症、狭心症、老化、免疫疾患または癌であることを特徴とする請求項4に記載の組成物。
- 前記砒素化合物は、三酸化砒素(As2O3)、六酸化砒素(As4O6)、三臭化砒素(AsBr3)、三塩化砒素(AsCl3)、三ヨウ化砒素(AsI3)及びメラルソプロール(Melarsoprol)からなる群で選択されることを特徴とする請求項1または4に記載の組成物。
- 前記組成物が、砒素化合物3〜5重量部、丁香17〜22重量部、全蠍220〜250重量部、鏡面朱砂22〜27重量部、牛黄27〜31重量部、ビャッキョウサン55〜62重量部、白附子41〜46重量部、枯白礬55〜62重量部、紫河車220〜250重量部及び竜脳2〜4重量部を含むことを特徴とする請求項1または4に記載の組成物。
- 丁香、全蠍、鏡面朱砂、牛黄、ビャッキョウサン、白附子、枯白礬、紫河車、竜脳及び砒素化合物を含む抗酸化組成物であって、
前記組成物が砒素化合物1〜7重量部、丁香15〜25重量部、全蠍200〜270重量部、鏡面朱砂20〜30重量部、牛黄25〜35重量部、ビャッキョウサン50〜65重量部、白附子38〜48重量部、枯白礬50〜65重量部、紫河車200〜270重量部及び竜脳0.5〜6重量部を含むことを特徴とする組成物 を含むことを特徴とする組成物。 - 丁香、全蠍、鏡面朱砂、牛黄、ビャッキョウサン、白附子、枯白礬、紫河車、竜脳及び砒素化合物を含む、砒素化合物の毒性低減用組成物であって、
前記組成物が砒素化合物1〜7重量部、丁香15〜25重量部、全蠍200〜270重量部、鏡面朱砂20〜30重量部、牛黄25〜35重量部、ビャッキョウサン50〜65重量部、白附子38〜48重量部、枯白礬50〜65重量部、紫河車200〜270重量部及び竜脳0.5〜6重量部を含むことを特徴とする組成物 を含むことを特徴とする組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0032471 | 2012-03-29 | ||
KR1020120032471A KR101391148B1 (ko) | 2012-03-29 | 2012-03-29 | 면역 관련 질환 및 산화적 스트레스 관련 질환의 예방 또는 치료용 조성물 |
PCT/KR2013/002556 WO2013147513A1 (ko) | 2012-03-29 | 2013-03-27 | 면역 관련 질환 및 산화적 스트레스 관련 질환의 예방 또는 치료용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015511636A JP2015511636A (ja) | 2015-04-20 |
JP6117333B2 true JP6117333B2 (ja) | 2017-04-19 |
Family
ID=49260692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015503120A Active JP6117333B2 (ja) | 2012-03-29 | 2013-03-27 | 免疫関連疾患及び酸化的ストレス関連疾患の予防または治療用組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9072721B2 (ja) |
JP (1) | JP6117333B2 (ja) |
KR (1) | KR101391148B1 (ja) |
CN (1) | CN104203261B (ja) |
WO (1) | WO2013147513A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101391148B1 (ko) | 2012-03-29 | 2014-05-07 | 옥은희 | 면역 관련 질환 및 산화적 스트레스 관련 질환의 예방 또는 치료용 조성물 |
CN104257738A (zh) * | 2014-09-30 | 2015-01-07 | 丁延强 | 治疗冠心病的心脑通中药制剂 |
US10447910B2 (en) * | 2016-08-04 | 2019-10-15 | International Business Machines Corporation | Camera notification and filtering of content for restricted sites |
KR101834366B1 (ko) | 2016-11-21 | 2018-03-05 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
US20180241973A1 (en) * | 2017-02-21 | 2018-08-23 | Janet Newell | Video and audio recording system and method |
KR102251247B1 (ko) * | 2018-08-16 | 2021-05-12 | 유상기 | 협심증 치료용 약학 조성물 및 그 제조방법 |
CN113712993A (zh) * | 2021-09-07 | 2021-11-30 | 上海交通大学医学院附属新华医院 | 三氧化二砷及其水溶物在制备治疗特应性皮炎药物中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61277625A (ja) * | 1985-06-04 | 1986-12-08 | Osaka Chem Lab | 生体牛から牛黄を製造する方法 |
KR950000165A (ko) * | 1993-06-02 | 1995-01-03 | 김우식 | 악성종양(암) 및 aids치료용 약제 및 그 제조방법 |
CN1052885C (zh) * | 1993-10-12 | 2000-05-31 | 焦晓 | 一种戒除鸦片毒品的中草药 |
KR20000015793A (ko) * | 1997-03-21 | 2000-03-15 | 겜마 아키라 | 면역강화제 |
CN1174062A (zh) * | 1997-07-18 | 1998-02-25 | 迟经惠 | 食道癌膏 |
KR100272835B1 (ko) | 1998-05-08 | 2000-11-15 | 배일주 | 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물 |
KR100712658B1 (ko) | 2005-03-30 | 2007-05-02 | 정두수 | 암치료용 한약조성물 |
JP2008201765A (ja) * | 2007-01-26 | 2008-09-04 | Jichi Medical Univ | 腫瘍治療における三酸化二ヒ素の副作用低減剤及び解毒剤 |
KR20100055638A (ko) * | 2008-11-18 | 2010-05-27 | 서정희 | 산삼 추출물을 유효성분으로 함유하는 면역 저하 억제용 약학적 조성물 |
KR101391148B1 (ko) | 2012-03-29 | 2014-05-07 | 옥은희 | 면역 관련 질환 및 산화적 스트레스 관련 질환의 예방 또는 치료용 조성물 |
-
2012
- 2012-03-29 KR KR1020120032471A patent/KR101391148B1/ko active IP Right Grant
-
2013
- 2013-03-27 US US14/382,800 patent/US9072721B2/en active Active
- 2013-03-27 JP JP2015503120A patent/JP6117333B2/ja active Active
- 2013-03-27 CN CN201380012621.5A patent/CN104203261B/zh not_active Expired - Fee Related
- 2013-03-27 WO PCT/KR2013/002556 patent/WO2013147513A1/ko active Application Filing
Also Published As
Publication number | Publication date |
---|---|
KR101391148B1 (ko) | 2014-05-07 |
CN104203261B (zh) | 2017-02-22 |
US9072721B2 (en) | 2015-07-07 |
CN104203261A (zh) | 2014-12-10 |
KR20130110466A (ko) | 2013-10-10 |
WO2013147513A1 (ko) | 2013-10-03 |
US20150017253A1 (en) | 2015-01-15 |
JP2015511636A (ja) | 2015-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6117333B2 (ja) | 免疫関連疾患及び酸化的ストレス関連疾患の予防または治療用組成物 | |
US20160151440A1 (en) | A Novel Composition of Curcumin with Enhanced Bioavailability | |
JP6656316B2 (ja) | ハマナツメの使用方法、ハマナツメ抽出物の使用方法及び薬物混合物の使用方法 | |
Pai et al. | Evaluation of hypolipidemic effects of Lyciumbarbarum (Goji berry) in a murine model | |
Aboulthana et al. | Assessment of the biological activities of Egyptian purslane (Portulaca oleracea) extract after incorporating metal nanoparticles, in vitro and in vivo study | |
WO2011158247A1 (en) | A novel herbal formulation for the prevention and management of type-2 diabetes mellitus and vascular complications associated with diabetes | |
KR100516180B1 (ko) | 항고지혈증 조성물 | |
JP2023540069A (ja) | チョウセンノギク抽出物を含む疼痛緩和用または抗酸化用健康機能食品 | |
KR101679480B1 (ko) | 천연 추출물을 함유하는 여드름 개선용 화장료 조성물 | |
KR101179966B1 (ko) | 항염증 효과를 갖는 관절염 치료를 위한 약제학적 조성물 | |
Ogbole et al. | Hepatoprotective and Antidyslipidemic Activities of Methanolic Extract of Garcinia kola Leaves in Streptozotocin-Induced Diabetic Rats | |
Rakebizadeh et al. | Supplemental effect of zinc oxide nanoparticles and mentha spicata butanol extract on blood glucose of diabetic wistar rats | |
Hijazi et al. | Studying Anti-inflammatory and Anti-Peptic Ulcer Effects of Aqueous Extract of Red Beetroots on Male Rats. | |
KR20170088478A (ko) | 인울산 추출물을 유효성분으로 포함하는 항산화, 항염증 및 항당뇨용 조성물 | |
JP2016069366A (ja) | 医薬組成物 | |
CN101062314A (zh) | 一种治疗痛风的药物及其制备方法 | |
KR20190098685A (ko) | 아위버섯의 추출물 또는 분말을 유효성분으로 함유하는 지방간 질환 치료용 약학적 조성물 및 간기능 개선용 건강기능식품 | |
Dadar et al. | Supplemental Effect of Zinc Oxide Nanoparticles and Prangos ferulacea Butanol Extract on Blood Glucose of Diabetic Wistar Rats | |
Kamalakkannan et al. | Studies on the effect of antidiabetic activity of Achyranthes aspera L. on alloxan induced wistar rats | |
Megha et al. | Polyphenol rich passion fruit inhibits Fenton’s reagent induced lipid peroxidation in rabbit colon | |
Yazhlini et al. | ANTI-INFLAMMATORY ACTIVITY OF Symplocos racemosa (LODHRA) AND Cinnamomum cassia (CINNAMON BARK) ASSISTED SILVER NANOPARTICLES | |
JP2014155489A (ja) | サルトリイバラ葉抽出物を含有する糖尿予防及び治療用の組成物 | |
Verma et al. | Anti-inflammatory effect of hydroalcoholic extract of hibiscus rosa on acute and chronic inflammation | |
Anaziah | The Effects of Cashew (Anacardium Occidentale) Leaves Extract On The Histology Of The Liver, kidney, and Small Intestine of Wistar Rats. | |
Cecil et al. | BIOFABRICATION OF ZINC OXIDE NANOPARTICLES USING CINNAMON AND LODHRA BARK FORMULATION AND ITS ANTI INFLAMMATORY ACTIVITY. SOWBARANIYA SM Saveetha Dental College and hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-600077, Tamil Nadu, India, Email. id: 151801094. sdc@ saveetha. com |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141110 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20141110 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170127 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170322 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6117333 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |